Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome
出版年份 2023 全文链接
标题
Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome
作者
关键词
-
出版物
CANADIAN JOURNAL OF CARDIOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2023-04-27
DOI
10.1016/j.cjca.2023.04.018
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention
- (2022) Remo H.M. Furtado et al. Circulation-Cardiovascular Interventions
- Novel method for quantification of lipoprotein(a)-cholesterol: Implications for improving accuracy of LDL-C measurements
- (2021) Calvin Yeang et al. JOURNAL OF LIPID RESEARCH
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
- (2020) Vera A. Bittner et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
- (2020) Sotirios Tsimikas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome
- (2020) Gregory G. Schwartz et al. CIRCULATION
- Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery Disease
- (2020) Jonathan Golledge et al. Journal of the American Heart Association
- Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
- (2020) Michael Szarek et al. EUROPEAN HEART JOURNAL
- Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization
- (2020) Kazuma Oyama et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events
- (2020) Peter Willeit et al. Journal of the American Heart Association
- Effect of Alirocumab on Mortality After Acute Coronary Syndromes
- (2019) Philippe Gabriel Steg et al. CIRCULATION
- NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis
- (2018) Sotirios Tsimikas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
- (2018) Peter Willeit et al. LANCET
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab
- (2017) Byambaa Enkhmaa et al. JOURNAL OF LIPID RESEARCH
- A Test in Context: Lipoprotein(a)
- (2017) Sotirios Tsimikas JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
- (2014) Gregory G. Schwartz et al. AMERICAN HEART JOURNAL
- Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry
- (2014) Dharam J. Kumbhani et al. EUROPEAN HEART JOURNAL
- Lipoprotein(a)-cholesterol: A significant component of serum cholesterol
- (2011) Kiyoko Kinpara et al. CLINICA CHIMICA ACTA
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
- (2009) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comparison of Effectiveness of Atorvastatin 10 mg Versus 80 mg in Reducing Major Cardiovascular Events and Repeat Revascularization in Patients With Previous Percutaneous Coronary Intervention (Post Hoc Analysis of the Treating to New Targets [TNT] Study)
- (2008) Colleen Johnson et al. AMERICAN JOURNAL OF CARDIOLOGY
- Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery
- (2008) Sanjiv J. Shah et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started